Barbara Pereira Mello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Barbara Pereira Mello has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Charles M. Rudin
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 shared publications Dennis Kinyua
2 shared publicationsElisa de Stanchina
2 shared publicationsEsther Redin
2 shared publicationsHarsha Sridhar
2 shared publicationsIrina Linkov
2 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Elsevier in Translational Oncology
- Vol. 71
SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma
- 20 July 2026
- Published by Elsevier in Translational Oncology
- Vol. 71
Open AccessSMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma
- Open Access
- 26 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
FOXA2 promotes metastatic competence in small cell lung cancer
Small cell lung cancer (SCLC) is known for its high metastatic potential, with most patients demonstrating clinically evident metastases in multiple organs at diagnosis. The factors contributing to this exceptional metastatic capacity have not been defined. To bridge this gap, we compare gene expression in SCLC patient samples who never experienced metastasis or relapse throughout their clinical course, versus primary SCLC patient samples from more typical patients who had metastatic disease at diagnosis. This analysis identifies FOXA2 as a transcription factor strongly associated with SCLC metastasis. Subsequent analyses in experimental models demonstrates that FOXA2 induces a fetal neuroendocrine gene expression program and promotes multi-site metastasis. Moreover, we identify ASCL1, a transcription factor known for its initiating role in SCLC tumorigenesis, as a direct binder of the FOXA2 promoter and regulator of FOXA2 expression. Taken together, these data define the ASCL1-FOXA2 axis as a critical driver of multiorgan SCLC metastasis.
- 26 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessFOXA2 promotes metastatic competence in small cell lung cancer
Small cell lung cancer (SCLC) is known for its high metastatic potential, with most patients demonstrating clinically evident metastases in multiple organs at diagnosis. The factors contributing to this exceptional metastatic capacity have not been defined. To bridge this gap, we compare gene expression in SCLC patient samples who never experienced metastasis or relapse throughout their clinical course, versus primary SCLC patient samples from more typical patients who had metastatic disease at diagnosis. This analysis identifies FOXA2 as a transcription factor strongly associated with SCLC metastasis. Subsequent analyses in experimental models demonstrates that FOXA2 induces a fetal neuroendocrine gene expression program and promotes multi-site metastasis. Moreover, we identify ASCL1, a transcription factor known for its initiating role in SCLC tumorigenesis, as a direct binder of the FOXA2 promoter and regulator of FOXA2 expression. Taken together, these data define the ASCL1-FOXA2 axis as a critical driver of multiorgan SCLC metastasis.
- 1 December 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (12) , 2343-2352.e3
Air Particulate Matter Induces Skin Barrier Dysfunction and Water Transport Alteration on a Reconstructed Human Epidermis Model
- 1 December 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (12) , 2343-2352.e3
Air Particulate Matter Induces Skin Barrier Dysfunction and Water Transport Alteration on a Reconstructed Human Epidermis Model